Literature DB >> 4853602

Pharmacokinetics of pindolol in man.

R Gugler, W Herold, H J Dengler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4853602     DOI： 10.1007/bf00614385

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  18 in total

1.  Proof of the general validity of Dost's law of corresponding areas.

Authors:  E Nüesch
Journal:  Eur J Clin Pharmacol       Date:  1973-06       Impact factor: 2.953

2.  Pharmacokinetics of dextro-, laevo- and racemic propranolol in man.

Authors:  C F George; T Fenyvesi; M E Conolly; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

3.  [Quantitative determination of protein binding of drugs by gel filtration].

Authors:  J Krieglstein; G Kuschinsky
Journal:  Arzneimittelforschung       Date:  1968-03

4.  Effect of a new adrenergic beta-blocking agent (ICI 50,172) on heart rate in relation to its blood levels.

Authors:  J D Fitzgerald; B Scales
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1968

5.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

6.  Studies with LB 46, a new beta-receptor blocking drug.

Authors:  I Lubawski; J Wale
Journal:  Eur J Pharmacol       Date:  1969       Impact factor: 4.432

7.  Drug urinary excretion data--some aspects concerning the interpretation.

Authors:  B K Martin
Journal:  Br J Pharmacol Chemother       Date:  1967-02

8.  Cardiovascular effects of prinodolol (LB-46), a potent beta-adrenergic receptor antagonist.

Authors:  J V Levy
Journal:  J Clin Pharmacol New Drugs       Date:  1971 Jul-Aug

9.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

10.  Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man.

Authors:  R C Hill; P Turner
Journal:  Br J Pharmacol       Date:  1969-06       Impact factor: 8.739
View more
  35 in total

1.  Beta-Adrenoceptor studies. 4. Influence of albumin on in vitro beta-adrenoceptor blocking and antiarrhythmic properties of propranolol, pindolol, practolol and metoprolol.

Authors:  J Zaagsma; L Meems; M Boorsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-05       Impact factor: 3.000

Review 2.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Bioavailability of beta-adrenoceptor blocking drugs.

Authors:  G Johnsson; C G Regardh
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

Review 4.  Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.

Authors:  W H Frishman; E J Lazar; G Gorodokin
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 5.  Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.

Authors:  Y Yamada; K Matsuyama; K Ito; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

6.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

Review 7.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

8.  Stereoselective renal clearance of pindolol in humans.

Authors:  P H Hsyu; K M Giacomini
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

9.  Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.

Authors:  N Himori; S Honma; A Izumi; T Ishimori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

10.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.